Cancer Research UK, Cytovation and the Norwegian Cancer Society announce a multi-national phase II clinical trial (CLARITY; ISRCTN15479264) for people with advanced adrenocortical carcinoma, a rare and aggressive cancer affecting the adrenal glands. The trial currently has multiple sites open in the UK with further sites planned across the UK and Europe.
The SANRECO phase II trial of divesiran, a first-in-class siRNA, in 48 phlebotomy-dependent patients with polycythemia vera, met its primary endpoint and secondary endpoints. The 36-week, randomized, double-blind, placebo-controlled portion of the trial administered divesiran subcutaneously (6 mg/kg) every six weeks or every twelve weeks.
